Jefferson University Hospitals

Physician Profile

Pierluigi Porcu, MD

Jefferson University Physician

Academic Title: Professor
Director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation

Specialties
Medical Oncology
Medical Oncology - Hematologic Malignancies
Medical Oncology - Leukemia/Lymphoma

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Medical Services

Board Certifications

  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Personal Statement

I am a Physician Scientist focused on T/NK-cell lymphomas and EBV-associated lymphomas. My goal is to offer patients a roadmap to understand their illness, find the determination to fight, select the best treatment and move forward with confidence. My overarching principle is patient empowerment based on knowledge. The more people know, the more prepared they are to face adversities. Knowledge guides expectations and grounds hope in facts. Great cancer care is based on compassion and research.

Education

  • Univ di Torino, Italy, Medical School

Internship

  • Indiana University Medical Center

Recent Publications

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome

Expanding and expounding the genomic map of CTCL

A positive randomised trial in cutaneous T-cell lymphoma

T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase-9 via a C-C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft Dysfunction

Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas

Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL)

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

Overview of the use of murine models in leukemia and lymphoma research

Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?

MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

Chronic effects of air pollution on lung function after lung transplantation in the Systems prediction of Chronic Lung Allograft Dysfunction (SysCLAD) study

Sézary Syndrome: Clinical and Biological Aspects

Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases

Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases

Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma

NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma

NKp80 Defines a Critical Step during Human Natural Killer Cell Development